Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2009
10/22/2009WO2009127878A1 A liquid spray solution comprising buprenorphine, ethanol and an antioxidant
10/22/2009WO2009127869A2 New Use
10/22/2009WO2009127833A1 Steroid nebuliser formulation
10/22/2009WO2009127825A1 Topical combinations comprising an antimycotic agent and an antiviral agent
10/22/2009WO2009127822A2 Bis-aryl compounds for use as medicaments
10/22/2009WO2009127815A1 Aminoalyl-imidazotetrazines for treatment of cancer
10/22/2009WO2009127802A1 Rosiglitazone composition
10/22/2009WO2009127737A1 Use of enantiomer (1s, 2r) of milnacipran hydrochloride for the preventive treatment of suicidal behaviour in depressed patients
10/22/2009WO2009127723A1 New arylsulphonylglycine derivatives, the preparation thereof and their use as medicaments
10/22/2009WO2009127686A1 Novel estrogen receptor ligands
10/22/2009WO2009127679A1 Indoles as modulators of nicoticic acetylcholine receptor subtype alpha-7
10/22/2009WO2009127678A1 Indoles as modulators of nicotinic acetylcholin receptor subtype alpha-71
10/22/2009WO2009127669A2 Ido inhibitors and therapeutic uses thereof
10/22/2009WO2009127642A2 Use of lrrk2 inhibitors for neurodegenerative diseases
10/22/2009WO2009127623A1 Crystalline (6r,7r)-7-{2-(5-amino-[1,2,4]thiadiazol-3-yl)-2-[(z)-trityloxyimino]-acetylamino}-3-[(r)-1'-tert-butoxycarbonyl-2-oxo-[1,3']bipyrrolidinyl-(3e)-ylidenemethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester; its manufacture and use
10/22/2009WO2009127612A1 Novel pyrazole derivatives
10/22/2009WO2009127609A1 Spirocyclic derivatives as histone deacetylase inhibitors
10/22/2009WO2009127546A1 Pyrrolidinone glucokinase activators
10/22/2009WO2009127544A1 Pyridazinone glucokinase activators
10/22/2009WO2009127417A1 Quinoline derivatives as axl kinase inhibitors
10/22/2009WO2009127398A2 Conjugated linoleic acid derivatives
10/22/2009WO2009127338A1 Oxo-heterocyclic substituted carboxylic acid derivates and the use thereof
10/22/2009WO2009127321A1 Benzofurane, benzothiophene, benzothiazol derivatives as fxr modulators
10/22/2009WO2009127320A1 Tertiary amine derivatives as phosphodiesterase-4 inhibitors
10/22/2009WO2009127283A1 Use of a composition containing healing earth as an antacid
10/22/2009WO2009127251A1 Combinations comprising a renin inhibitor
10/22/2009WO2009127218A1 Derivatives of galantamine as pro-drugs for the treatment of human brain diseases
10/22/2009WO2009127210A1 Vasodilating agents for the treatment of sleep attacks
10/22/2009WO2009127116A1 13-halo-3,15-dioxy gibberellic acid esters and the preparation methods thereof
10/22/2009WO2009127072A1 Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use
10/22/2009WO2009127060A1 Novel lipid formulations for nucleic acid delivery
10/22/2009WO2009127059A1 Complexes of isogranulatimide and granulatimide with a cyclodextrm, formulations and their use for the treatment of cancer
10/22/2009WO2009127057A1 Cosmetic compositions comprising exopolysaccharides derived from microbial mats, and use thereof
10/22/2009WO2009127048A1 Method of treating demyelinating diesase
10/22/2009WO2009108383A3 Substituted xanthine derivatives
10/22/2009WO2009106960A3 Stable compositions of lamivudine, tenofovir and efavirenz
10/22/2009WO2009103494A3 Sgk1 as a therapeutic and diagnostic target for carcinomatous diseases
10/22/2009WO2009102820A3 Modified sugar substrates and methods of use
10/22/2009WO2009102428A3 1,3-OXAZEPAN-2-ONE AND 1,3-DIAZEPAN-2-ONE INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1
10/22/2009WO2009102172A3 Pharmaceutical formulation containing choline alfoscerate
10/22/2009WO2009101475A3 Use of glycosylceramides for enhancing the immune response to antigens
10/22/2009WO2009100936A3 Novel aromatic fluoroglycoside derivatives, pharmaceuticals comprising said compounds, and the use thereof
10/22/2009WO2009100218A3 Kruppel-like transcription factor klf4/gklf and uses thereof
10/22/2009WO2009099959A3 Tumor cell expression of neuropilin as a target for cancer therapy
10/22/2009WO2009099820A3 Modulating body weight
10/22/2009WO2009099650A3 Treatment of bladder diseases with a tlr7 activator
10/22/2009WO2009098490A9 Antimicrobial agents for the treatment of campylobacter species in the crop of a bird
10/22/2009WO2009097113A3 Oxazole and thiazole compounds as b-catenin modulators and uses thereof
10/22/2009WO2009097095A9 Methods for treating hematopoietic malignancies
10/22/2009WO2009094577A3 Mesophasic forms of calcium-salts of (3s)-aminomethyl-b-methyl-hexanoic acids and methods of use
10/22/2009WO2009093264A3 Pharmaceutical combinations comprising specified age breaker and further drugs, i.a. antihypertensive drugs, antidiabetic drugs etc.
10/22/2009WO2009092129A8 Delayed release pharmaceutical composition of duloxetine
10/22/2009WO2009091605A3 Taste titration therapies
10/22/2009WO2009088992A3 Ribonuclease and thiazolidinedione compounds and their use in methods to treat cancer
10/22/2009WO2009084975A8 Composition exhibiting high osmotic antimicrobial, anti-inflammatory and regeneration activity
10/22/2009WO2009084974A8 1,3-dialkyl-benzimidazole halogenides exhibiting regeneration, anti-inflammatory and antimicrobial activity
10/22/2009WO2009082819A8 Novel lupane derivatives
10/22/2009WO2009080351A9 Compounds with anti-emetic effect
10/22/2009WO2009077956A3 HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM
10/22/2009WO2009073192A3 Systems and methods for delivery of materials
10/22/2009WO2009063493A3 Topical pharmaceutical composition for the combination of fusidic acid and a corticosteroid
10/22/2009WO2009045505A3 Prohormones for increasing sexual performance
10/22/2009WO2009004339A3 Modulation of reactive oxygen species in the treatment of respiratory infection
10/22/2009WO2009000907A3 Combination of picotamide with nafronyl
10/22/2009WO2008128189A9 Anti-cancer compositions and methods
10/22/2009WO2008117154A3 Stable pharmaceutical compositions, preferably tablets, of hmg-coa reductase inhibitor and process for preparation thereof
10/22/2009WO2008089103A8 Targeting ncca-atp channel for organ protection following ischemic episode
10/22/2009WO2008071961A8 2-quinolinone and 2-quinoxalinone- derivatives and their use as antibacterial agents
10/22/2009WO2008032162A8 Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
10/22/2009US20090265798 Desaturase genes and uses thereof
10/22/2009US20090265796 DNA segment that confers increased episomal stability, persistence or abundance of the isolated DNA molecule in a host cell; genetic engineering
10/22/2009US20090264855 Method and Device for Transdermal Electrotransport Delivery of Fentanyl and Sufentanil
10/22/2009US20090264647 Benzoimidazole compounds
10/22/2009US20090264646 Benzoimidazole compounds
10/22/2009US20090264645 Benzoimidazole compounds
10/22/2009US20090264642 Anhydrous crystal of bata-lactam compound and method for preparation thereof
10/22/2009US20090264600 Method for Preparing Water-Soluble Polymer Derivatives Bearing a Terminal Carboxylic Acid
10/22/2009US20090264537 Biodegradable block copolymeric compositions for drug delivery
10/22/2009US20090264535 Liquid drug formulation
10/22/2009US20090264534 Selective androgen receptor modulators
10/22/2009US20090264533 Methods and Compositions for Modulating RHO-Mediated Gene Transcription
10/22/2009US20090264531 Sulindac formulations in a biodegradable material
10/22/2009US20090264530 Combined nsaid and acetaminophen formulation and method
10/22/2009US20090264529 Activators of peroxisome proliferator-activated receptors
10/22/2009US20090264528 Serine palmitoylcoa transferase (spt) inhibition by myriocin or genetic deficiency decreases cholesterol absorption
10/22/2009US20090264527 Method for stabilizing retinoic acid, retinoic acid containing composition, and method of using a retinoic acid containing composition
10/22/2009US20090264526 Natural ligand of G protein coupled receptor RCC356 and uses thereof
10/22/2009US20090264525 Fluorosurfactants
10/22/2009US20090264524 Agent for recovery from cerebral fatigue
10/22/2009US20090264523 Method for Prevention of Degradation of Thermally Unstable Medicament
10/22/2009US20090264522 Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
10/22/2009US20090264521 Percutaneous absorption preparation
10/22/2009US20090264520 Lipid-containing compositions and methods of use thereof
10/22/2009US20090264519 Insulin sensitivity improving agent
10/22/2009US20090264518 Liquid koji and quick-brewed miso-like food
10/22/2009US20090264517 Milbemycin compounds and treatment of dermatological disorders in humans therewith
10/22/2009US20090264516 Milbemycin compounds and treatment of dermatological disorders in humans therewith
10/22/2009US20090264515 Polynucleotide therapy
10/22/2009US20090264514 SPHINGOMYELIN SYNTHASE 2 (SMS2) DEFICIENCY ATTENUATES NFkB ACTIVATION, A POTENTIAL ANTI-ATHEROGENIC PROPERTY
10/22/2009US20090264513 Expression vector
1 ... 2527 2528 2529 2530 2531 2532 2533 2534 2535 2536 2537 2538 2539 2540 2541 2542 2543 2544 2545 2546 2547 ... 7860